vs
Side-by-side financial comparison of RE/MAX Holdings, Inc. (RMAX) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RE/MAX Holdings, Inc. is the larger business by last-quarter revenue ($71.1M vs $57.3M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). RE/MAX Holdings, Inc. runs the higher net margin — 2.0% vs -83.0%, a 85.0% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -1.8%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -4.7%).
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
RMAX vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.1M | $57.3M |
| Net Profit | $1.4M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 13.1% | -82.2% |
| Net Margin | 2.0% | -83.0% |
| Revenue YoY | -1.8% | 36.9% |
| Net Profit YoY | -75.2% | -9.6% |
| EPS (diluted) | — | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.1M | $57.3M | ||
| Q3 25 | $73.2M | $51.3M | ||
| Q2 25 | $72.8M | $48.5M | ||
| Q1 25 | $74.5M | $32.7M | ||
| Q4 24 | $72.5M | $41.8M | ||
| Q3 24 | $78.5M | $33.3M | ||
| Q2 24 | $78.5M | $29.1M | ||
| Q1 24 | $78.3M | $26.0M |
| Q4 25 | $1.4M | $-47.5M | ||
| Q3 25 | $4.0M | $-52.9M | ||
| Q2 25 | $4.7M | $-46.6M | ||
| Q1 25 | $-2.0M | $-49.5M | ||
| Q4 24 | $5.8M | $-43.3M | ||
| Q3 24 | $966.0K | $-43.6M | ||
| Q2 24 | $3.7M | $-32.3M | ||
| Q1 24 | $-3.4M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 13.1% | -82.2% | ||
| Q3 25 | 25.0% | -102.6% | ||
| Q2 25 | 19.3% | -93.4% | ||
| Q1 25 | 7.2% | -143.7% | ||
| Q4 24 | 5.9% | -98.6% | ||
| Q3 24 | 19.4% | -132.0% | ||
| Q2 24 | 20.6% | -139.2% | ||
| Q1 24 | 5.8% | -538.7% |
| Q4 25 | 2.0% | -83.0% | ||
| Q3 25 | 5.4% | -103.1% | ||
| Q2 25 | 6.4% | -96.1% | ||
| Q1 25 | -2.6% | -151.4% | ||
| Q4 24 | 8.0% | -103.6% | ||
| Q3 24 | 1.2% | -131.2% | ||
| Q2 24 | 4.7% | -110.9% | ||
| Q1 24 | -4.3% | -544.4% |
| Q4 25 | — | $-0.73 | ||
| Q3 25 | — | $-0.82 | ||
| Q2 25 | — | $-0.75 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | — | $-0.55 | ||
| Q1 24 | — | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $118.7M | $388.9M |
| Total DebtLower is stronger | $432.2M | — |
| Stockholders' EquityBook value | $452.4M | $139.1M |
| Total Assets | $582.5M | $480.2M |
| Debt / EquityLower = less leverage | 0.96× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $118.7M | $388.9M | ||
| Q3 25 | $107.5M | $416.1M | ||
| Q2 25 | $94.3M | $291.0M | ||
| Q1 25 | $89.1M | $314.5M | ||
| Q4 24 | $96.6M | $320.6M | ||
| Q3 24 | $83.8M | $298.4M | ||
| Q2 24 | $66.1M | $319.1M | ||
| Q1 24 | $82.1M | $201.2M |
| Q4 25 | $432.2M | — | ||
| Q3 25 | $433.3M | — | ||
| Q2 25 | $434.4M | — | ||
| Q1 25 | $435.3M | — | ||
| Q4 24 | $436.2M | — | ||
| Q3 24 | $437.2M | — | ||
| Q2 24 | $438.1M | — | ||
| Q1 24 | $439.0M | — |
| Q4 25 | $452.4M | $139.1M | ||
| Q3 25 | $448.1M | $148.8M | ||
| Q2 25 | $442.4M | $-11.9M | ||
| Q1 25 | $433.5M | $18.9M | ||
| Q4 24 | $429.5M | $21.7M | ||
| Q3 24 | $423.1M | $11.2M | ||
| Q2 24 | $418.4M | $39.3M | ||
| Q1 24 | $412.0M | $61.6M |
| Q4 25 | $582.5M | $480.2M | ||
| Q3 25 | $582.2M | $506.9M | ||
| Q2 25 | $574.8M | $372.7M | ||
| Q1 25 | $571.4M | $386.7M | ||
| Q4 24 | $581.6M | $392.3M | ||
| Q3 24 | $578.6M | $363.6M | ||
| Q2 24 | $571.4M | $381.8M | ||
| Q1 24 | $566.7M | $258.7M |
| Q4 25 | 0.96× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 0.98× | — | ||
| Q1 25 | 1.00× | — | ||
| Q4 24 | 1.02× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.05× | — | ||
| Q1 24 | 1.07× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $40.9M | $-25.4M |
| Free Cash FlowOCF − Capex | $33.5M | — |
| FCF MarginFCF / Revenue | 47.1% | — |
| Capex IntensityCapex / Revenue | 10.4% | — |
| Cash ConversionOCF / Net Profit | 28.39× | — |
| TTM Free Cash FlowTrailing 4 quarters | $56.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.9M | $-25.4M | ||
| Q3 25 | $17.7M | $-26.6M | ||
| Q2 25 | $4.6M | $-23.3M | ||
| Q1 25 | $5.7M | $-40.4M | ||
| Q4 24 | $59.7M | $-18.8M | ||
| Q3 24 | $17.6M | $-25.2M | ||
| Q2 24 | $15.9M | $-29.1M | ||
| Q1 24 | $9.4M | $-40.7M |
| Q4 25 | $33.5M | — | ||
| Q3 25 | $16.4M | — | ||
| Q2 25 | $2.9M | — | ||
| Q1 25 | $4.0M | — | ||
| Q4 24 | $53.0M | — | ||
| Q3 24 | $16.3M | — | ||
| Q2 24 | $14.0M | — | ||
| Q1 24 | $6.8M | — |
| Q4 25 | 47.1% | — | ||
| Q3 25 | 22.4% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 5.3% | — | ||
| Q4 24 | 73.2% | — | ||
| Q3 24 | 20.8% | — | ||
| Q2 24 | 17.8% | — | ||
| Q1 24 | 8.6% | — |
| Q4 25 | 10.4% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 28.39× | — | ||
| Q3 25 | 4.45× | — | ||
| Q2 25 | 0.97× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 10.28× | — | ||
| Q3 24 | 18.22× | — | ||
| Q2 24 | 4.29× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
RYTM
Segment breakdown not available.
